Speaking at BIO 2026, Kasper Øland, Samsung Biologics' vice president of sales execution, emphasizes how complex molecules now exceed 55% of the company’s pipeline as biotechs demand faster, more flexible CDMO partnerships.
Kasper Øland
Advertisement
Kasper Øland is vice president of sales execution for the CDO Services division of Samsung Biologics.
Articles by Kasper Øland
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5